Panzytrat ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 298 | Hereditary pancreatitis | 3 |
298. Hereditary pancreatitis
Clinical trials : 95 / Drugs : 148 - (DrugBank : 51) / Drug target genes : 53 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01430234 (ClinicalTrials.gov) | October 2011 | 1/9/2011 | Enzyme Suppletion in Exocrine Pancreatic Dysfunction | Enzyme Substitution in Exocrine Pancreatic Insufficiency; Self Administration Against a Fixed Dose Regimen | Chronic Pancreatitis;Exocrine Pancreatic Insufficiency | Drug: Panzytrat 25.000 FIP-E units of Lipase | Foundation for Liver Research | Axcan Pharma | Completed | 18 Years | 90 Years | Both | 10 | Phase 4 | Netherlands |
| 2 | EUCTR2010-020303-69-NL (EUCTR) | 19/09/2011 | 19/09/2011 | Enzyme substitution in exocrine pancreatic insufficiency; Self administration against a fixed dose regimen. - SAPES | Enzyme substitution in exocrine pancreatic insufficiency; Self administration against a fixed dose regimen. - SAPES | Exocrine pancreatic insufficiency in patients with chronic pancreatitis MedDRA version: 12.1;Level: LLT;Classification code 10041969;Term: Steatorrhoea | Trade Name: Panzytrat Product Name: Panzytrat Product Code: RVG 13760 INN or Proposed INN: pancreatic enzymes Other descriptive name: LIPASE | Erasmus MC | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Netherlands | |||
| 3 | EUCTR2004-002468-89-DE (EUCTR) | 28/10/2004 | 23/09/2004 | A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED PHASE IV TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PANCREATIN VS. PLACEBO FOR LIPID DIGESTION AND ABSORPTION IN PATIENTS WITH PANCREATIC EXOCRINE INSUFFICIENCY - Pancreatin vs. Placebo in Patients with Pancreatic Exocrine Insufficiency | A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED PHASE IV TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PANCREATIN VS. PLACEBO FOR LIPID DIGESTION AND ABSORPTION IN PATIENTS WITH PANCREATIC EXOCRINE INSUFFICIENCY - Pancreatin vs. Placebo in Patients with Pancreatic Exocrine Insufficiency | The purpose of this clinical trial is to evaluate the clinical efficacy and safety of a capsule containing enteric-coated porcine pancreatin microfilm tablets in comparison with placebo in the treatment of pancreatic exocrine insufficiency due to chronic pancreatitis. MedDRA version: 7.0;Level: LLT;Classification code 10033622 | Trade Name: Panzytrat 25.000 Product Name: Panzytrat 25.000 Product Code: Pancreatin INN or Proposed INN: Pancreatin | Axcan Pharma S.A. | NULL | Not Recruiting | Female: yes Male: yes | 20 | Phase 4 | Germany |